Drug Profile

EVOLVE 101

Alternative Names: EV-101 - EvolveImmune Therapeutics; EVOLVE-101

Latest Information Update: 27 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EvolveImmune Therapeutics
Class Antibodies; Antineoplastics; Immunotherapies; Recombinant proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

24 Oct 2022 EvolveImmune Therapeutics plans a first-in-human clinical trial in Acute myeloid leukaemia and Haematological malignancies in 2024
13 Jul 2022 Early research in Acute myeloid leukaemia in USA (Parenteral) (EvolveImmune Therapeutics pipeline, July 2022)
13 Jul 2022 Early research in Haematological malignancies in USA (Parenteral) (EvolveImmune Therapeutics pipeline, July 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com